Table 1 Demographic and Clinical Characteristics of Patients Exposed to Atypical Antipsychotics, November 2002-March 2005 (N = 49,946)
Characteristic | N (%) |
|---|---|
Sex | |
Male | 19,981 (40.0) |
Age (mean (s.d. a )) | 43.9 (19.2) |
Index Year | |
2002 | 5,407 (10.8) |
2003 | 24,438 (48.9) |
2004 | 18,186 (36.4) |
2005 | 1,914 (3.8) |
Past use of antipsychotics | |
Aripiprazole | 1,966 (3.9) |
Clozapine | 60 (0.1) |
Olanzapine | 13,826 (27.7) |
Quetiapine | 10,632 (21.3) |
Risperidone | 11,367 (22.8) |
Ziprasidone | 1,367 (2.7) |
First generation antipsychotics (typicals) | 1,714 (3.4) |
Pharmacotherapy exposure b | |
Alpha blockers | 1,975 (4.0) |
Beta blockers | 9,479 (19.0) |
Systemic corticosteroids | 12,254 (24.5) |
Fibrates | 960 (1.9) |
Lithium | 6,662 (13.3) |
Nogesterol oral contraceptives | 487 (1.0) |
Statins | 5,171 (10.4) |
Thiazide diuretics | 7,561 (15.1) |
Thiazide-related diuretics | 219 (0.4) |
Valproate | 10,314 (20.7) |
Hydantoin anticonvulsants | 1,020 (2.0) |
ICD-9 coded comorbidity | |
Obese | 2531 (5.1) |